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Killing Two Birds with One Drug: A New Application for HIV-i
Cell Entry Inhibitors in the Treatment of Metastatic Cancer
Abstract
The chemokine recpotors CCR5 and CXCR4 serve as co-recep
tors for tfe human immunodehdiency v/run 1 (H/V-i) and thus, are
important cellular components during HIV- 1 cell entry In recent
years, a new b/c/op/cal role for chemokine receptors has emerged
in assisting the spread of primary tumors to distant secondary sites
within the human body (metastasis). This review highlights some of
the H/V-i cell entry inhibitors (antagonists), which are currently in
development and/or under evaluation in clinical trials, and discusses
the therapeutic use of these new antagonists for the treatment of
certain forms of metasta tic cancer
Chemokines and chemokine receptors
The chemokines belong to a large family of small, chemotactic
cytokines. which play an important role in mediating inflamma
tory responses, leukocyte homing, and cell migration (chemotaxis)
in specific types of leukocytes. Chemokines are divided into four
suhfamilies (CC. CXC, C, and CX3C) characterized by a distinct
pattern of conserved cysteine residues°2. Chemokines mediate
their biological effects by binding to chemokine receptors. a fam
ily of seven transmembrane (7TM) receptors. which belong to the
G protein-coupled receptor (GPCR) superfamily (Figure 1). The
chemokine receptor family is divided into two main subclasses,
which consists of eleven CC (CCR I-Il) and six CXC receptors
(CXCRI-6). and also includes lymphotactin receptor XCRI and
the fractaline receptor CX3CRl’. The binding of chemokines
(agonists) to the receptor triggers a series of intracellular events
mediated by heterotrimeric G proteins, which ultimately leads to
actin polymerization and chemotaxis (Figure 1 )/
The role of chemokine receptors in HIV-1 cell
entry
The human immunodeticiencv virus 1 (l-llV— 1) enters its host cell by
sequential interaction with receptor CD4 and one of the chemokine
receptors! HIV- I co-receptors CCR5 orCXCR4 (Figure 1 Y”/ While
R5-tropic HIV- I strains initiate infection through interaction with
CCR5 and predominate during the period of’ clinical latency. the
more virulent CXCR4-interacting X4-tropic H IV- I strains are found
late in infection and after AIDS symptoms appearh However, many
primary clinical isolates are dual—tropic and can use either CCR5 or
CXCR4 to infect the host cellsh Although many other chemokine
receptor subsets also have HIV- I co-receproractivity in vitm. a func
tion in v/co has primarily been demonstrated for CCR5 and CXCR4,
Most impressively, a clear role for CCR5 in HIV— 1 pathogenesis has
been found through the discovery of a naturally occurring. 32—hp
André S Bachmann PhD, Assistant Professor’
Natural Products and cancer Biology Program
cancer Research center of Hawaii,
and Ivonne Gamper MS, Graduate Student
*corresponding Author: abachmann@crch.hawaii.edu
deletion mutant in the human CCR5 gene (CCR5A32) that renders
homozygotes highly resistant to HIV— I infection’.
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Development of new Hay-I cell entry
inhibitors
The recognition that chemokine receptors junction
as co—receptors and assist the cell entry of l-HV- I
fueled the interest in this family of receptor proteins.
which resulted in a significant increase in published
literature after 1995 (Figure 2). The exploration ol
chemokine receptors as potential therapeutic targets
followed soon after and led to the development ot
a number of HIV-l cell entry inhibitors (e.g. TAK
779 and AMD3 100) and derivatives leg. TAK-22(t
and .—\MD070, which are currently in development
or entering clinical phase trials (Table I) . Fhce
ntagnit peciticall block the binding of the 1IIV-
ens elope protein tEns to either C’( kS or (‘XCR4
and thLis lorm a new generation of anti-HIV drug’.
ss hieh may be used in combination with existing
pro1eae and reverse—traosenp[a’e RT inhihitor to
treat HIV- I infoction A number ol phannaceutical
companies are leading in the discovers ol cell entr
inhibitors, including Schering Plough. (laxo Smith
Kline. Pfi,’er. Millennium. Merck. Takeda. \o arti.
and Astra /eneea.
Table I Represeni five exam s of CCR5 and CXCR4 antagontsts
ClinicalReceptor Antagonist Triah Comments
CCR5 TA10779 Phase First non-peptidic inhibitor, discontnued
TAK-220 Phase Derivative of TAK-779, orally bioavaiiabie
SCHC Phase Also called SCH 351125. orally hioavalable. discontinued
SCH-D Phase Ii More potent in vitro than SCH-C, orals Oioavaiiabie
AD1 01 NA Also called SCH 350581 overiappino b:ndings sites wif.h SCHC
8913 NA Inhibits multidrugresistant HIOl orals Oaavai.abie
CMPD f 57 NA Also called MRRf effective :n SlVE:nfec.1ed rhesus m.acaaues
GW873140 Phase S Orally bi.oavalabie
iJi<.4278.57 Phase lOll Derha.iive ci UK177543, oral5 cc•.avalabO
CXC0:” Ar,n’”r P’asv SIrS
AM.311’l S—aye ii Deroai.v ci AM[)3 77. “cliv s:ec
Ai7D205 N A Deria:’,e ci
KFHr930 NA And HO Doi:e 5”:l’c.At,1D’_7
Riven-c c Ce Cyroc 2775: Hork 2003-1 and R.Oeac S Hoc” 2775
S-nec! oeceiopme1 mane accorong I0 oaosnec I!eraLre ancc aseoved ‘‘c”rnl.c” on Ire
NA. ‘tc’rn-aicn on cuiren! ce’e-conrenr cage cci avalage 0’ macs ,inciear
number of published articles in PubMed inttp www nco’.nlrn nih.govi from 1988 to 2004 using the seaiui
CXCR4”. The number ot published artices increased ‘apidly after the discovery that CCR5 and OXCR4
nombor of articles re ects the PuoMed “esults obtained wth the indicated search terms on y.
articles, Other symbo s sjcn as us’n or GXGR c OKR5 for CCR5) were not incuded as
A role for chemokine receptors in
cancer metastasis
In many cancers, metastasis is the leading cause of
mortality. Despite extensive research. Ihe precise
mechanisms h which cancer cells are disseminated
to sites distant from the primary tumor are not fully
understood, While the chemokine-mcdiated cell mi
gration of leukoc tes has lone been known, it has
only recently been found that tumor cells may utilize
similar mechanisms during cancer meiastasis. It has
been proposed that subsets of chcmokine receptors
are expressed b certain tumor cells and that specific
chemokines are highly expressed at sites of cancer
metastasis, thus su!eestin that speci tic combinations
f chemokines and chcmokine receptors determine
the final destination of nietactanc tumor cells
This concept i’ supported b several reports. which
describe the expression of a distinct non—random
pattern of subsets of functionally active chemokine
receptors, such as CXCR3 and C’XCR4 in human
melanomaceHs5°,CXCR4 in metastatic breast cancer
cells, and CCR7 and CCR 10 in skin metastases.
Other evidence for the role of chemokine receptors
in cancer metastasis include the findings that CCR5
i’ expressed on stronial cells and thereh promotes
pulnionar metastasis and that the upreulation of
C\CR4 is essential for HER2—mediated breast tumor
inetastasis. Moreover. the relevance of cheniokine
receptors in 1110 was demonstrated li usine CX(’R4—
specific antihodics. which significantly reduced the
FigJ”e 3.— Human neurobias:oma NB) cells express endogenous XOR4 B. 0. Fl. but not CCR5 A. C. El. LAN
1. NMB-7. and SK-N-SH cci s wee incubated wth OXOR4 or CCR5-recogriz ng primary moroclona antibodies and
FlTc- aneled secondary antioody or secondary antibody alone as a contro’. Cell surface stained ccl s were measured
by flow cytonletry (FACScam and data were evaluated using the program eliQuest. NB cells were cultured as previ
ousy descibed
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formation of lymph node and lung metastases in immunodehcient
mice and by stud ing CCR5 knockout juice ((‘CR51. ‘ hich
developed fewer metastases
Expression of chemokine receptor CXCR4 in
human neuroblastoma cells
The expression of cheniokine receptors was initially thought to he
restricted to leukocvtes However, there is now clear evidence that
they are also expressed in neurons’ as well as neuroblastoma (NB)
tumors2125.NB is a pediatric cancer, in which malignant cells form
in the nerve tissue of the adrenal gland. neck. chest, or spinal cord.
Metastatic dissemination of L3 occurs hr hemogenous and lym
phatic pathways to F mph nudes, hone. and hone marrow. Recent
studies reported the presence of endogenous (‘XCR4 in NB cells-
and our own data sviih three human NB cell lines confirmed their
obser alions Figure 3. In contrast. ‘s e did not detect any CCR5
protein in thesecells. which is in accordance with previously reported
findings using the NB cell line SH—SY5Y. a suhclone ofSK—N-SH-’.
A biological role for CXC’R4 in the development of bone marrow
metastases was proposed. thus further underlining the importance
of CXCR424
Potential application of HIV-1 cell entry inhibi
tors as anti-metastatic drugs
The recognition that CCR5 and CXCR4 play a crucial role in certain
forms of cancer metastasis clearly suggests that HIV— I cell entrr
inhibitors, which are generally safe and well tolerated in HIV— I
patients, should be exploited in clinical cancer trials. These anti—
metastatic drugs ma’s act in several ‘s’sar 5: hr preventing the metastatic
spread of primary tumor cells. h\ inhibiting macruphage infiltrates.
and by induction of chemukine receptor—mediated tumor cell arrest
and programmed cell death tapoptosis)’’’. In gain more insights
into the role of CXCR—I my laboratory is interested in exploring the
efiects ofHJV— I cell entr inhibitors on the migration, differentiation.
and apoptosis of human NB eel Is with the ultimate goal to develop
novel therapeutics for high-risk NB patients.
Conclusions
It is intriguing to speci late that HIV— I cell entry inhibitors could
pro’s e to he useful therapeutics fur the prevention and treatment of
metastasis of (‘CR5— or CXC’R4—associated tumors. Furthermore,
the development of antagonists that speciticallx block the function
of other chemokine receptors will further contribute to formulating
selective anti—metastatic therapies. whic Ii are likely to reduce un
wanted side effects in patients. i’he screening of a larger number of
cancer patients Will be necessary to better define the expression pat
tern of chemokine receptors in metastatic tumors. Such information,
combined with an effort to determine a cancer patient’s individual
chemokine receptor profile prior to treatment, will allow a more per—
sonalized patient care with improved therapeutic outcome. Finally.
chemokines are also with a number of autoinflammatorr
diseases including multiple sclerosis, rheumatoid arthritis, diabetes.
and endometriosic, further stiggestin a wide range of therapeutic
ippI icatiuns for ehemokine receptor antagonists - -
‘r ua ‘re in formal ion abs ut the ( (ancer Research Center of 1—1 ass ai i -
inlease ‘sisit our ‘svebsite at ‘sv’svw,crch,ore.
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Surfe.’s Medical Association: Conference in Biarritz, France
The f/nsa Eu’orear rr.eetlna of twa SMA nW be held 0om
SetemCser 30 o ‘Dc5ccer 9, 2005 The oonference mcci toe ‘:1
to cn,’s:o.vInS (InCa flea’ -c.im Oro:eSs:OrCun ‘,‘.‘ro
:ns )42:t:C”t( ‘cnd;or .,‘.,‘h .me nofers 9Tfl5ei JEan.
The conferensoe orogram mU) (nch:,J.de presentatons by a))
affendees to uc:date the status of the hea(ih-care/surhna inter
face plus networking w(th internatiorsa) colleagues. Additional
detayr are o a blnr or he M.Th eL (C4 Sc waamoon wa ) F
th.e events sectio.n.
The conference registration fee of $2,200 gOD includes one
oceanfront room (based on doub(e oocuoancy) for ten n)hts..
three meals. her day and ground transoc.rt e’ach day to s,cr.i,u.:lt,,
ed surf snots.
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